The study was carried out at the Centre for Global Health Research (CGHR) CDC-KEMRI located about 10 Km from Kisumu City along the Kisumu-Busia road. The station lies on the coordinates 0°4'40"N 34°40'38"E. Kisumu City, in western Kenya, is an area endemic for major infectious diseases including malaria. Research Design This study employed an experimental research design and followed the post-test only assessment. Two groups were randomly selected, the experimental and control groups, with the latter comprising of positive and negative controls. The positive controls contained the recommended 1 g/L of Bi-Larv TM 25 WP (a registered trademark product of Bayer Pharmaceutics Company in wettable powder containing 25% diflubenzuron, an insect growth regulator (IGR) as the active ingredient, and is listed under WHO Pre-Qualification (WHO-PQ) scheme) while the negative controls contained 1 mL acetone in 250 mL solution.